Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Sponsor: Gilead Sciences
This PHASE1 trial investigates Breast Cancer and Colorectal Cancer and is currently completed. Gilead Sciences leads this study, which shows 16 recorded versions since 2013 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
16 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jul 2020 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 11 earlier versions
-
Jun 2020 — Jul 2020 [monthly]
Completed PHASE1
-
Jun 2019 — Jun 2020 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Mar 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE1
-
Sep 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE1
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jun 2017 — Mar 2018 [monthly]
Recruiting PHASE1
-
Apr 2017 — Jun 2017 [monthly]
Recruiting PHASE1
-
Mar 2017 — Apr 2017 [monthly]
Recruiting PHASE1
-
Feb 2017 — Mar 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Mar 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Gilead Sciences
For direct contact, visit the study record on ClinicalTrials.gov .